SWOG 1937: A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

February 23, 2021
https://clinicaltrials.gov/ct2/show/NCT04579224
Cancer - Kidney, Cancer - Bladder
Principal Investigator: Ding Wang, MD
CANCER, KIDNEY CANCER, KIDNEY, BLADDER CANCER, BLADDER, URETER, UROTHELIAL, UROTHELIAL CANCER
In Progress